急性骨髓性白血病是成人常見(jiàn)的白血病類型，發(fā)病率隨年齡的增長(zhǎng)而升高，病情進(jìn)展迅速，嚴(yán)重威脅人類健康。恩西地平（Enasidenib，Idhifa^®）是第一個(gè)異檸檬酸脫氫酶2抑制劑，能有效治療該酶變異導(dǎo)致的急性骨髓性白血病，也是美國(guó)食品藥品管理局批準(zhǔn)的唯一一個(gè)針對(duì)這一患者群體的腫瘤代謝療法新藥。對(duì)恩西地平的作用機(jī)制、藥效學(xué)、藥動(dòng)學(xué)、藥物相互作用、臨床評(píng)價(jià)和安全性等進(jìn)行綜述，旨在為臨床應(yīng)用提供有益的參考。

Acute myelocytic leukemia (AML) is a common type of leukemia massively afflicting the adults. The incidence of the disease increases with age with aggressive development, which pose a severe threaten to human health. Enasidenib (Idhifa^®) is the first inhibitor against isocitrate dehydrogenase2 (IDH2), which is globally approved by FDA for the potent treatment of adults with refractory IDH2-mutated AML as well as represents a sole therapy through regulating cancer metabolism for the patients with AML. The mechanism, pharmacodynamics, pharmacokinetics, drug interaction, clinical evaluation, and safety of Enasidenib were reviewed to provide the beneficial reference for the clinic application in the near future.